Immunomodulatory activity of interferon-beta

Annals of Clinical and Translational Neurology

Volumn 1, Issue 8, 2014, Pages 622-631

  Kasper, Lloyd H ^a   Reder, Anthony T ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; CD86 ANTIGEN; GAMMA INTERFERON RECEPTOR 1; GELATINASE B; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; INTERFERON REGULATORY FACTOR; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; JANUS KINASE; MATRIX METALLOPROTEINASE; MYELOID DIFFERENTIATION FACTOR 88; NATALIZUMAB; OCRELIZUMAB; RITUXIMAB; STAT PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TRANSFORMING GROWTH FACTOR BETA;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CEREBROSPINAL FLUID; DEMYELINATION; ESCHERICHIA COLI; EXPERIMENTAL ALLERGIC ENCEPHALITIS; GENE EXPRESSION; HUMAN; INTESTINE FLORA; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VIRUS INFECTION;

EID: 84924724500     PISSN: None     EISSN: 23289503     Source Type: Journal    
DOI: 10.1002/acn3.84     Document Type: Review

References (65)

1. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502–1517.
2. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002;58:S3–S9.
3. Kasper LH, Shoemaker J. Multiple sclerosis immunology: the healthy immune system vs the MS immune system. Neurology 2010;74(suppl 1):S2–S8.
4. Bekisz J, Sato Y, Johnson C, et al. Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res 2013;33:154–161.
5. Runkel L, Meier W, Pepinsky RB, et al. Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). Pharm Res 1998;15:641–649.
6. Owens GP, Gilden D, Burgoon MP, et al. Viruses and multiple sclerosis. Neuroscientist 2011;17:659–676.
7. Ochoa-Reparaz J, Mielcarz DW, Begum-Haque S, et al. Gut, bugs, and brain: role of commensal bacteria in the control of central nervous system disease. Ann Neurol 2011;69:240–247.
8. Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011;479:538–541.
9. Lee YK, Menezes JS, Umesaki Y, et al. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2011;108(suppl 1):4615–4622.
10. Engelhardt B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008;274:23–26.
11. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010;74(suppl 1):S17–S24.
12. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507–3512.
13. Nuyts A, Lee W, Bashir-Dar R, et al. Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies? Mult Scler 2013;19:995–1002.
14. Kaisho T. Pathogen sensors and chemokine receptors in dendritic cell subsets. Vaccine 2012;30:7652–7657.
15. Bayas A, Stasiolek M, Kruse N, et al. Altered innate immune response of plasmacytoid dendritic cells in multiple sclerosis. Clin Exp Immunol 2009;157:332–342.
16. Zamvil S, Nelson P, Trotter J, et al. T-cell clones specific for myelin basic protein induce chronic relapsing paralysis and demyelination. Nature 1985;317:355–358.
17. Balashov KE, Aung LL, Vaknin-Dembinsky A, et al. Interferon-beta inhibits toll-like receptor 9 processing in multiple sclerosis. Ann Neurol 2010;68:899–906.
18. Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006;129:1293–1305.
19. Ifergan I, Kebir H, Alvarez JI, et al. Central nervous system recruitment of effector memory CD8+ T lymphocytes during neuroinflammation is dependent on alpha4 integrin. Brain 2011;134:3560–3577.
20. Jiang H, Milo R, Swoveland P, et al. Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells. J Neuroimmunol 1995;61:17–25.
21. Derkow K, Bauer JM, Hecker M, et al. Multiple sclerosis: modulation of toll-like receptor (TLR) expression by interferon-beta includes upregulation of TLR7 in plasmacytoid dendritic cells. PLoS One 2013;8:e70626.
22. Vallittu AM, Saraste M, Airas L. CCR7 expression on peripheral blood lymphocytes is up-regulated following treatment of multiple sclerosis with interferon-beta. Neurol Res 2007;29:763–766.
23. Li Q, Milo R, Panitch H, et al. Effect of propranolol and IFN-beta on the induction of MHC class II expression and cytokine production by IFN-gamma IN THP-1 human monocytic cells. Immunopharmacol Immunotoxicol 1998;20:39–61.
24. Gravano DM, Hoyer KK. Promotion and prevention of autoimmune disease by CD8+ T cells. J Autoimmun 2013;45:68–79.
25. Lee MA, Palace J, Stabler G, et al. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 1999;122(Pt 2):191–197.
26. Waubant E, Goodkin D, Bostrom A, et al. IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS. Neurology 2003;60:52–57.
27. Boz C, Ozmenoglu M, Velioglu S, et al. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta. Clin Neurol Neurosurg 2006;108:124–128.
28. Stadelmann C, Kerschensteiner M, Misgeld T, et al. BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002;125:75–85.
29. Correale J, Villa A. Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010;67:625–638.
30. Durelli L, Conti L, Clerico M, et al. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol 2009;65:499–509.
31. Baeten DL, Kuchroo VK. How cytokine networks fuel inflammation: interleukin-17 and a tale of two autoimmune diseases. Nat Med 2013;19:824–825.
32. Wang X, Ma C, Wu J, et al. Roles of T helper 17 cells and interleukin-17 in neuroautoimmune diseases with emphasis on multiple sclerosis and Guillain-Barre syndrome as well as their animal models. J Neurosci Res 2013;91:871–881.
33. Pan HF, Li XP, Zheng SG, et al. Emerging role of interleukin-22 in autoimmune diseases. Cytokine Growth Factor Rev 2013;24:51–57.
34. Beyeen AD, Adzemovic MZ, Ockinger J, et al. IL-22RA2 associates with multiple sclerosis and macrophage effector mechanisms in experimental neuroinflammation. J Immunol 2010;185:6883–6890.
35. Antel J, Arnason BG. Pathogenesis of multiple sclerosis. Eur J Clin Invest 1977;7:461–463.
36. Reder AT, Antel JP, Oger JJ, et al. Low T8 antigen density on lymphocytes in active multiple sclerosis. Ann Neurol 1984;16:242–249.
37. Fritzsching B, Haas J, Konig F, et al. Intracerebral human regulatory T cells: analysis of CD4+ CD25+ FOXP3+ T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PLoS One 2011;6:e17988.
38. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207–210.
39. Comabella M, Rio J, Espejo C, et al. Changes in matrix metalloproteinases and their inhibitors during interferon-beta treatment in multiple sclerosis. Clin Immunol 2009;130:145–150.
40. Dhib-Jalbut S, Sumandeep S, Valenzuela R, et al. Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. J Neuroimmunol 2013;254:131–140.
41. Guo B, Chang EY, Cheng G. The type I IFN induction pathway constrains Th17-mediated autoimmune inflammation in mice. J Clin Invest 2008;118:1680–1690.
42. Mascanfroni ID, Yeste A, Vieira SM, et al. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol 2013;14:1054–1063.
43. Caminero A, Comabella M, Montalban X. Tumor necrosis factor alpha (TNF-alpha), anti-TNF-alpha and demyelination revisited: an ongoing story. J Neuroimmunol 2011;234:1–6.
44. Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997;185:1573–1584.
45. Yong VW, Chabot S, Stuve O, et al. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998;51:682–689.
46. Lowther DE, Chong DL, Ascough S, et al. Th1 not Th17 cells drive spontaneous MS-like disease despite a functional regulatory T cell response. Acta Neuropathol 2013;126:501–515.
47. Feng X, Yau D, Holbrook C, et al. Type I interferons inhibit interleukin-10 production in activated human monocytes and stimulate IL-10 in T cells: implications for Th1-mediated diseases. J Interferon Cytokine Res 2002;22:311–319.
48. Genc K, Dona DL, Reder AT. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest 1997;99:2664–2671.
49. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4:557–567.
50. Huang H, Ito K, Dangond F, et al. Effect of interferon beta-1a on B7.1 and B7.2 B-cell expression and its impact on T-cell proliferation. J Neuroimmunol 2013;258:27–31.
51. Ireland S, Monson N. Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int 2011;2011:423971.
52. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779–1787.
53. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460–471.
54. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455–1463.
55. Krumbholz M, Theil D, Derfuss T, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005;201:195–200.
56. Meinl E, Krumbholz M, Hohlfeld R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006;59:880–892.
57. Graber JJ, Ford D, Zhan M, et al. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J Neuroimmunol 2007;185:168–174.
58. Croze E, Yamaguchi KD, Knappertz V, et al. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J 2013;13:443–451.
59. Rudick RA, Rani MR, Xu Y, et al. Excessive biologic response to IFNbeta is associated with poor treatment response in patients with multiple sclerosis. PLoS One 2011;6:e19262.
60. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008;7:796–804.
61. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49:351–357.
62. Fox E, Wynn D, Cohan S, et al. A randomized clinical trial of autologous T-cell therapy in multiple sclerosis: subset analysis and implications for trial design. Mult Scler 2012;18:843–852.
63. Hartung HP, Kieseier BC. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010;3:205–216.
64. Castillo-Trivino T, Braithwaite D, Bacchetti P, et al. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013;8:e66308.
65. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15–23.